> Details

Schmoll, Hans-Joachim; Garlipp, Benjamin; Junghanss, Christian; Leithaeuser, Malte; Vogel, Arndt; Schaefers, Michael; Kaiser, Ulrich; Hoeffkes, Heinz-Gert; Florschütz, Axel; Rüssel, Jörn; Kanzler, Stephan; Edelmann, Thomas; Forstbauer, Helmut; Goehler, Thomas; Hannig, Carla; Hildebrandt, Bert; Steighardt, Jörg; Meinert, Fabian Maximilian; Cygon, Franziska; Stein, Alexander

CHARTA: FOLFOX+bevacizumab +/- irinotecan in advanced colorectal cancer (CRC)—Final results of the randomized phase II trial of the AIO (KRK 0209)

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: CHARTA: FOLFOX+bevacizumab +/- irinotecan in advanced colorectal cancer (CRC)—Final results of the randomized phase II trial of the AIO (KRK 0209)
  • Contributor: Schmoll, Hans-Joachim; Garlipp, Benjamin; Junghanss, Christian; Leithaeuser, Malte; Vogel, Arndt; Schaefers, Michael; Kaiser, Ulrich; Hoeffkes, Heinz-Gert; Florschütz, Axel; Rüssel, Jörn; Kanzler, Stephan; Edelmann, Thomas; Forstbauer, Helmut; Goehler, Thomas; Hannig, Carla; Hildebrandt, Bert; Steighardt, Jörg; Meinert, Fabian Maximilian; Cygon, Franziska; Stein, Alexander
  • imprint: American Society of Clinical Oncology (ASCO), 2017
  • Published in: Journal of Clinical Oncology
  • Language: English
  • DOI: 10.1200/jco.2017.35.4_suppl.658
  • ISSN: 0732-183X; 1527-7755
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: <jats:p> 658 </jats:p><jats:p> Background: The 4-drug-regimen FOLFOXIRI+Bevacizumab (Bev) was superior to FOLFIRI+Bev (TRIBE F.Loupakis, NEJM 2014). CHARTA investigates the same 4-drug-regimen vs. FOLFOX+Bev. Methods: 250 patients were randomized from 7/11 to 12/14 to standard FOLFOX+Bev (A) vs. FOLFOXIRI+Bev (B), with dose/schedule as in TRIBE, 25% dose reduction in cycle 1 + 2, if necessary. Incl.criteria: ECOG 0-2, ≥ 1 measurable lesion &gt; 1cm; stratified by ESMO-Group 1, 2, 3 (HJ Schmoll et. al., Ann Oncol 2012). Induction: 6 months, maintenance Capecitabine+Bev until progression or max. of 12 months, with reinduction by individual decision. Primary EP: significant improvement of PFS-rate at 9 months (p&lt;0.1, 2-sided Fisher’s-exact test); secondary EP: RR- rate, PFS, OS, sec. resection. Results: Evaluable 241 pts. (1 not elig., 8 prot. violation); m/f: 65%/35%, age 61 yrs. (21-82), left/right: left A: 51, 5%, B: 48, 5%; right A: 45%, B: 55%; ECOG 0-1/2: 96% / 4%, ESMO-group 1/2/3: 29%/ 55%/ 16%. Primary endpoint was met: significantly improved PFS at 9 months 56% vs. 68% (p= 0,086). Preliminary PFS 9,76 vs. 12,0 months (HR 0.77, p=0.61), identical to TRIBE: 9.7 vs. 12.1. Response (A/B): CR: 5/5%, CR/PR 60/70%, SD 25/21%, PD 14/9%; sec. resection: 21/23%. Subgroup - analyses did not show significant differences, except CR / PR left/right (A/B): left 59/68%, right 63/73%; PFS (months) left 10.4/12 (HR 0.69, p=0.03), right: 8.2 /10.7); non-significant improvement in ESMO-group 3 (HR 0.51), RAS-wt (HR 0.67), Koehne-Score High risk HR 0.58; ECOG 1: HR 0.69. QL-Global- Health-Score: slightly worse in A, vs. improved in B. Dose-intensity &lt;70%/ 70-90%/ &gt;90% (A/B): 39/37%/ 18/26%/ 41%/36%; initial dose-reduction 17% of pts. Toxicity: low to moderate without major differences between A &amp;B, except grade ¾ diarrhea 12/16%, neutrophils 14/20%, GI 12/20%. Conclusions: The 4-drug-regimen has superior activity with the same outcome as TRIBE and is well tolerated, without a negative effect of initial dose-reduction, and an improvement of global QoL-Score. Final PFS, OS data and detailed subgroup/multivariate analysis, including Quality of life data, will be presented. Clinical trial information: NCT01321957. </jats:p>
  • Access State: Open Access